Reimbursed Care Access in Spain

Currently classified as a strictly controlled substance under national drug scheduling laws, with no authorized medical use outside of approved clinical research. #

Currently classified as a strictly controlled substance under national drug scheduling laws, with no authorized medical use outside of approved clinical research. (Enforcement and large seizures continue to demonstrate illegal status in Spain.) #

Esketamine (marketed as Spravato) is authorized in Spain for adults with treatment‑resistant major depressive disorder when used in combination with an oral antidepressant and under specialist supervision; full product information and the national 'Informe de Posicionamiento Terapéutico' are published by the Agencia Española de Medicamentos y Productos Sanitarios (AEMPS). # #

Reimbursement and access: despite AEMPS authorization and national IPT guidance, Spravato is not routinely included as a standard reimbursed product across the Spanish National Health System (SNS); access in practice often requires hospital‑level exceptional procurement or individual hospital budget approval, and many patients currently access rapid glutamatergic therapy through private provision. Media reporting and professional commentary note ongoing price/negotiation issues between Janssen and national health payers which have limited broad public reimbursement. #

Practical delivery model: Spravato is delivered in specialist settings (psychiatry/hospital day‑units) under monitored conditions (blood pressure monitoring, supervised administration) as required by the product labelling; initiation and maintenance schedules are defined in the technical dossier. Where public funding is not available, private clinics or hospital‑approved exception procedures are used (self‑pay or hospital budget approval). #

Ketamine (the racemate or generic ketamine formulations) is a legally authorized medicinal product for anesthetic and analgesic indications, and is used off‑label in Spain for treatment‑resistant depression and other psychiatric indications as an unlicensed/experimental therapeutic approach when prescribed by physicians. Hospitals and private clinics administer intravenous or intranasal ketamine infusions under medical supervision; these services are typically provided on a private/self‑pay basis because there is no standardized, nationwide SNS reimbursement pathway for ketamine infusions for psychiatric indications. #

Regulatory and clinical context: because ketamine is an approved anesthetic agent, clinicians may legally procure and prescribe it; however, its psychiatric use is considered off‑label and local hospital policies, informed consent, and specialist oversight are expected. There is active interest in research and some hospitals/centres run clinical protocols, but standardized SNS coverage for ketamine for depression is not in place—patients commonly pay privately or receive treatment under individual hospital exceptions. #

Currently classified as a strictly controlled substance under national drug scheduling laws, with no authorized medical use outside of approved clinical research. (Standalone DMT is treated as a controlled psychotropic; however see separate entry for ayahuasca as a plant preparation legal‑grey area.) #

Currently classified as a strictly controlled substance under national drug scheduling laws, with no authorized medical use outside of approved clinical research. #

Currently classified as a strictly controlled substance under national drug scheduling laws, with no authorized medical use outside of approved clinical research. (There is no recognized, reimbursed medical ibogaine programme in Spain.) #

Ayahuasca (as a whole plant brew) occupies a judicial and administrative grey zone in Spain: several court decisions have distinguished complex plant decoctions containing naturally occurring DMT from the standalone scheduled substance, producing case law that has de‑facto allowed private ceremonial / traditional use where there is no evidence of trafficking, profit motive or public health risk. This jurisprudential approach means ayahuasca retreats and private ceremonial use have flourished in parts of Spain, but the legal permissiveness is fragile and fact‑specific; authorities have also conducted police operations against commercialised/unsafe retreats where trafficking, public health risks or criminality were alleged. # #

Operational and access implications: because ayahuasca is not explicitly scheduled as a plant preparation, certain private groups have operated retreats in Spain; however organisers run legal risk (investigations/prosecutions) if activities appear commercialized, unsafe, or linked to trafficking. Recent reporting indicates both growth in retreats and targeted law‑enforcement actions against operations alleged to involve trafficking or public health offences, underscoring the unstable legal climate. #

Currently classified as a strictly controlled substance under national drug scheduling laws, with no authorized medical use outside of approved clinical research. (Cacti/plant matters such as San Pedro or peyote may raise distinct legal questions, but the mescaline alkaloid itself is controlled.) #

Currently classified as a strictly controlled substance under national drug scheduling laws, with no authorized medical use outside of approved clinical research. (2C‑family compounds such as 2C‑B were added to Spain's prohibited substance lists in the early 2000s.) #